Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeEAM conditioning regimen in autologous stem cell transplantation for relapsed lymphoma
IRCT20180622040187N1Phase 4Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Mar 2017
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bendamustine, etoposide, cyclophosphamide, cytarabine, melphalan and 1 more in lymphoma, sponsored by Shiraz University of Medical Sciences. Primary endpoints: Median time to engraftment, 6-month survival and 12 more. Started Mar 2017; status: completed.
02
Drugs
bendamustineetoposidecyclophosphamidecytarabinemelphalan
03
Conditions
lymphoma
Beyond the preview
Go deeper on IRCT20180622040187N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180622040187N1.